Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.

David Moher; Cook; Jadad; Peter Tugwell; Moher; Jones; Pham; Klassen

doi:10.3310/hta3120

Abstract

1 min read

T he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources.

Related publications

Article2000

Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

David Moher, Susan Eastwood, Ingram Olkin, Drummond Rennie, Donna F. Stroup

Article2000

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement

David Moher, Susan Eastwood, Ingram Olkin, Drummond Rennie, Donna F. Stroup

Article2002

Assessing the quality of reports of randomized trials in pediatric complementary and alternative medicine

David Moher, Margaret Sampson, Kaitryn Campbell, William Beckner, Leah Lepage, Isabelle Gaboury, Brian Berman

Article2002

Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine

David Moher, Karen L. Soeken, Margaret Sampson, Leah Ben‐Porat, Brian Berman

Article2022

Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme

Lis Cordingley, Pauline Nelson, Linda Davies, Darren M. Ashcroft, Christine Bundy, Carolyn Chew‐Graham, Anna Chisholm, Jamie Elvidge, Matthew Hamilton, Rachel Hilton, K. Kane, Chris Keyworth, Alison Littlewood, Karina Lovell, Mark Lunt, Helen McAteer, Dionysios Ntais, Rosa Parisi, Christina J. Pearce, Martin K. Rutter, Deborah Symmons, Helen Young, Christopher Em Griffiths